Influenza A (H7N9) monovalent vaccine

The influenza A (H7N9) monovalent vaccine is an inactivated or recombinant viral vaccine developed to provide active immunization against the avian-origin H7N9 subtype of the influenza A virus. This strain has pandemic potential and has caused severe illness in humans. The vaccine is typically formulated as an inactivated split-virion or subunit antigen, sometimes adjuvanted with AS03 to enhance immune response. It works by inducing the production of antibodies against the hemagglutinin protein of H7N9, thereby providing protection if exposed to this virus. The primary indication is for pre-pandemic preparedness and outbreak control among populations at risk[1][2][3][4]. Multiple companies have developed versions using established flu production platforms.

Other names

avian influenza a (h7n9) vaccineinactivated influenza a/h7n9 vaccine